Long-Term Outcomes of Children and Adolescents With Biopsy-Proven Childhood-Onset Lupus Nephritis.

Autor:	Chan EY; Paediatric Nephrology Center, Hong Kong Children's Hospital, Hong Kong.; Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong., Yap DY; Paediatric Nephrology Center, Hong Kong Children's Hospital, Hong Kong.; Division of Nephrology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong., Wong WT; Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong., Wong WH; Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong., Wong SW; Paediatric Nephrology Center, Hong Kong Children's Hospital, Hong Kong., Lin KY; Paediatric Nephrology Center, Hong Kong Children's Hospital, Hong Kong., Hui FY; Paediatric Nephrology Center, Hong Kong Children's Hospital, Hong Kong., Yee-Ming J; Paediatric Nephrology Center, Hong Kong Children's Hospital, Hong Kong., Lam SS; Paediatric Nephrology Center, Hong Kong Children's Hospital, Hong Kong., Wong JK; Paediatric Nephrology Center, Hong Kong Children's Hospital, Hong Kong., Lai FF; Paediatric Nephrology Center, Hong Kong Children's Hospital, Hong Kong., Ho TW; Paediatric Nephrology Center, Hong Kong Children's Hospital, Hong Kong., Tong PC; Paediatric Nephrology Center, Hong Kong Children's Hospital, Hong Kong., Lai WM; Paediatric Nephrology Center, Hong Kong Children's Hospital, Hong Kong., Chan TM; Paediatric Nephrology Center, Hong Kong Children's Hospital, Hong Kong.; Division of Nephrology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong., Ma AL; Paediatric Nephrology Center, Hong Kong Children's Hospital, Hong Kong.; Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong.
Jazyk:	angličtina
Zdroj:	Kidney international reports [Kidney Int Rep] 2022 Oct 21; Vol. 8 (1), pp. 141-150. Date of Electronic Publication: 2022 Oct 21 (Print Publication: 2023).
DOI:	10.1016/j.ekir.2022.10.014
Abstrakt:	Introduction: Long-term data pertaining to childhood-onset lupus nephritis (cLN) remain extremely scarce. Methods: We conducted a retrospective cohort study of biopsy-proven cLN with onset age <18 years diagnosed from 2001 to 2020 to ascertain the long-term patient and kidney survival rates, and the incidence of advanced chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] <60 ml/min per 1.73 m ² ). Results: A total of 92 subjects (78 female; age 13.7 ± 3.3 years; all Chinese) were included, with follow-up duration of 10.3 years (interquartile range, 5.8-15.9). Of these, 83 children (90%) had proliferative lupus nephritis (LN) (Class III/IV ± V). Mycophenolate was used for induction in 36%, whereas 34% received cyclophosphamide (CYC); 55% received mycophenolate as maintenance immunosuppression. The rates of complete remission (CR) and partial remission (PR) at 6 months and 12 months, respectively, were 65% and 20% and 78% and 8%. Two patients died (mortality rate 2.1/1000 patient-years), with a standardized mortality ratio of 22.3. Three patients (3.2%) developed end-stage kidney disease (ESKD), and advanced CKD occurred in 5 patients (5.4%). Survival rates without advanced CKD, ESKD, or death were 96.7%, 94.2%, 92.7%, 83.2% and 83.2% at 1 year, 5 years, 10 years, 15 years, and 20 years, respectively. Multivariate analysis revealed that severe kidney failure necessitating dialysis at presentation (adjusted hazard ratio 37.7, 95% confidence interval [CI] 4.0-355.6, P = 0.002), nonresponse (NR) after 12 months of treatment (adjusted hazard ratio 11.2, 95% CI 2.3-54.9, P = 0.003), and multiple nephritis flares (adjusted hazard ratio 2.6, 95% CI 1.1-6.2, P = 0.03) were predictive of advanced CKD, ESKD, or death. Other adverse outcomes included infections (2.9 episodes/100 patient-years), osteopenia (32%), hypertension (17%), short stature (14%), and avascular necrosis (7%). Conclusion: The long-term outcomes of cLN appeared to have improved in the present era with effective immunosuppression, cautious drug tapering, and assurance of medication adherence. There is still an unacceptably high prevalence of adverse outcomes. (© 2022 Published by Elsevier Inc. on behalf of the International Society of Nephrology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu